Activation of the neurokinin-1 receptor is known to induce proliferation in tumor cells, but it is as yet unknown whether this applies to retinoblastoma. This was an in vitro study of the growth inhibitory capacity of the potent and long-acting neurokinin-1 receptor antagonist L-733,060, at concentrations ranging from 7.5 to 20 M, against the human retinoblastoma line WERI-Rb-1 and from 10 to 25 M against the human retinoblastoma line Y-79. The ability of substance P (an neurokinin-1 stimulator) to activate the cell growth of these retinoblastoma cell lines was also determined. METHODS. A cell counter was used to determine the number of viable cells, followed by application of the tetrazolium compound WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4 nitrophenyl))-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt, colorimetric method to evaluate cell viability in this cytotoxicity assay. RESULTS. Nanomolar concentrations of substance P increased the growth of both cell lines and micromolar concentrations of L-733,060 inhibited the growth of the two cell lines studied, with and without previous administration of substance P. 1 This tumor comprises 3% of tumors recorded in children younger than the age of 15 years and represents one of the most common malignant tumors of childhood, with an incidence of 1 in 15,000 live births and an increased frequency in patients with a positive family history of retinoblastoma. 2, 3 This malignancy leads to metastatic disease and death in 50% of children worldwide but in less than 5% of children in developed nations with advanced medical care. 4 Several new methods are currently being developed to improve the success rates of eye preservation (60%) with useful visual functions. It is expected that in the near future newer and more effective anticancer drugs that are less toxic to normal tissues will become available for the treatment of retinoblastoma.
R etinoblastoma arises from the photoreceptor elements, poorly differentiated neuroblasts, of the inner layer of the retina. 1 This tumor comprises 3% of tumors recorded in children younger than the age of 15 years and represents one of the most common malignant tumors of childhood, with an incidence of 1 in 15,000 live births and an increased frequency in patients with a positive family history of retinoblastoma. 2, 3 This malignancy leads to metastatic disease and death in 50% of children worldwide but in less than 5% of children in developed nations with advanced medical care. 4 Several new methods are currently being developed to improve the success rates of eye preservation (60%) with useful visual functions. It is expected that in the near future newer and more effective anticancer drugs that are less toxic to normal tissues will become available for the treatment of retinoblastoma. 5 Substance P (SP) is an undecapeptide that belongs to the tachykinin family of peptides. It is known that SP, neurokinin A (NKA), neuropeptide K, and neuropeptide-␥ are derived from the preprotachykinin (PPT-1) A gene, whereas neurokinin B (NKB) is derived from the preprotachykinin (PPT-2) B gene. The biological action of SP, NKA and NKB are mediated by three receptors, named neurokinin (NK)-1, NK-2 and NK-3, the NK-1 receptor showing preferential affinity for SP. After binding to the NK1 receptor, SP regulates many biological functions, 6 -8 and this neuropeptide has also been implicated in neurogenic inflammation, pain, and depression. 9 Moreover, SP is known to have a widespread distribution in both the central and peripheral nervous systems and the undecapeptide is released from primary sensory nerve fibers. It is also known that activation of the NK1 receptor induces mitogenesis in several tumoral cells. 10 -13 Moreover, SP immunoreactivity has been demonstrated, using an indirect immunofluorescence technique, in retinoblastoma cells. 14 L-733,060 is a selective, potent, and long-acting central nonpeptide tachykinin NK1 receptor antagonist showing high affinity for the human NK1 receptor in vitro. 15 It is known that administration of L-733,060 produces analgesia 15 and antidepressive effects. 16, 17 Furthermore, L-733,060 has been used in the treatment of a broad range of anxiety and mood disorders 18 and in inflammatory liver disease; its action is most probably due to an inhibition of the effects of SP. 19 In addition, we have recently reported that L-733,060 shows antitumoral activity against the human neuroblastoma, glioma, and melanoma cell lines. 13, 20 Several SP antagonists have been shown, in vitro and in vivo, to inhibit the growth of both small cell lung cancer and glioma. [21] [22] [23] [24] [25] However, to our knowledge, no study has been performed on the effect of the potent and long-acting NK1 receptor antagonist L-733,060 on human retinoblastoma cell lines (WERI-Rb-1, Y-79). It is also unknown whether SP exerts a mitogenic action on these tumor cell lines. Thus, the purpose of this study was to demonstrate, using a WST-8 colorimetric method to evaluate cell viability, the antitumoral action of the NK1 receptor antagonist L-733,060. A further intent was to study the role of SP on the induction of retinoblastoma WERIRb-1 and Y-79 cell proliferation.
MATERIALS AND METHODS

Cell Cultures
We used the human retinoblastoma cell lines WERI- The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
20% heat-inactivated fetal bovine serum respectively according to the culture conditions suggested by the manufacturer. Cell lines were subcultured in 75-cm 2 tissue culture flasks (Falcon, Heidelberg, Germany) and the medium was renewed once a week. Cells were incubated at 37°C in a humidified atmosphere of 95% air/5%CO 2 .
Drug Treatments
The NK1 receptor antagonist (2S,3S)3-( [3,5- 
Proliferation Assays
Cell proliferation was evaluated using the tetrazolium compound 
Statistical Analyses
The data were evaluated statistically using Student's t-test, taking P Յ 0.05 or Յ 0.01 as the level of significance.
RESULTS
Growth inhibition of the WERI-Rb-1 and Y-79 retinoblastoma cell lines by L-733,060 was observed after the addition of increasing concentrations of L-733,060 (Figs. 1A, 2A) . Moreover, treatment of both cell lines with L-733,060 resulted in a concentration-dependent cytotoxicity (Figs. 1A, 2A) . Thus, the concentrations required for a 50% reduction in optical density (IC 50 Growth of the WERI-Rb-1 and Y-79 cell lines was observed after the addition of SP, and it was observed that certain nanomolar concentrations of SP induced cell proliferation compared with the control cells (Figs. 1B, 2B ). SP stimulation was evident at 10 nM, the maximum level being reached at 100 nM for WERI-Rb-1 and Y-79 (Figs. 1B, 2B ). This indicates that the activation of SP receptors leads to mitogenesis in the WERIRb-1 and Y-79 human cancer cell lines. Thus, the percentage of cell proliferation of both cellular lines increased from 3% to 50% in WERI-Rb-1 and from 12% to 35% in Y-79, depending on the dose of SP administered (Figs. 1B, 2B) .
Treatment with L-733,060 at 10 M for WERI-Rb-1 and 15 M for Y-79 partially inhibited the growth of both cell lines (Figs. 1B, 2B ). To explore whether the NK1 receptor antago- 
DISCUSSION
We have demonstrated in vitro for the first time a potent growth inhibition on the human retinoblastoma WERI-Rb-1 and Y-79 cell lines after administration of the nonpeptide NK1 receptor antagonist L-733,060. This is in agreement with previous studies, in which the use of SP antagonists other than L-733,060 inhibited, both in vitro and in vivo, the growth of small-cell lung cancer. [21] [22] [23] [24] Our findings are also in agreement with recent reports showing that L-733,060 exerts antitumoral activity against other human cancer cell lines, such as neuroblastoma, glioma, and melanoma. 13, 20 It should be noted that in cell lines as different as human neuroblastoma, glioma, melanoma, and retinoblastoma the same NK1 receptor antagonist (L-733,060) elicits growth inhibition. This observation suggests the possibility of a common mechanism for cancer cell proliferation mediated by SP and NK1 receptors. Were this so, it would mean that NK1 receptor antagonists (e.g., L-733,060) could inhibit a large number of tumor cell types in which both SP and NK1 receptors are expressed, 14,26 -29 and could be a candidate as a broad-spectrum antineoplastic drug.
We have demonstrated that treatment of the retinoblastoma cell lines with L-733,060 produces growth inhibition and cell death. Currently, we do not know whether the cell death observed here was due to a general toxic effect of L-733,060 or to a specific action of this substance. Despite this, there are data suggesting the second possibility. Thus, the action on these cell lines by the NK1 receptor antagonist L-733,060 is probably related to the ability of this antagonist to block the NK1 receptor in such tumors. The blockade of NK1 receptors in both retinoblastoma cell lines by L-733,060 could inhibit both DNA synthesis and cell proliferation through the mitogenactivated protein kinase (MAPK) pathway.
10 L-733,060 could induce retinoblastoma cell death by apoptosis, as has been reported previously in vitro in lung cancer cell lines. 23 In this sense, it is known that an SP antagonist (other than L-733,060) induces apoptosis in lung cancer and causes a concentrationdependent loss of cell viability, 23 as we observed using L-733,060, since the antitumoral activity of L-733,060 reported herein was dose-dependent. These data therefore suggest that the antiproliferative action of the NK1 receptor antagonist L-733,060 could involve a signal transduction pathway for apoptosis. However, further studies in this field are necessary to know whether the cell death observed in our study was due to a general toxic effect or to a specific action associated with the ability of the L-733,060 to block NK1 receptor.
All the above data suggest that treatment with antagonists of the NK1 receptor in cancer cell lines expressing the NK1 receptor could improve cancer treatment. In this sense, it would be very interesting to know whether the treatment of cancer cell lines with the NK1 receptor inhibitors that have been studied in humans 30 might produce the same growthinhibiting action that we found with L-733,060. At present, there are more than 30 compounds that act as NK1 receptor antagonists. 31 We also demonstrated for the first time that SP increases the growth of retinoblastoma cell lines. This is consistent with the findings of previous studies, since it has been reported that the activation of NK1 receptors by SP induces mitogenesis in several cancer cell types 10 -13 and that the NK1 receptor is overexpressed in breast cancer and metastasis. 28 Moreover, substance P-immunoreactivity has been observed in retinoblastoma cells 14 and NK1 receptors have been described in the retina. 32 Finally, our results indicate that L-733,060 blocks SP mitogen stimulation, since L-733,060-induced growth inhibition was partially reversed by the administration of exogenous SP. This observation suggests that the NK1 receptor may play an important role in the growth of the retinoblastoma cell lines studied (Figs. 1B, 2B ), since after treatment with SP and L-733,060 increases in the cellular concentration (27.36% and 9.65%) were observed respectively in the WERI-Rb-1 and Y-79 cell lines (Figs. 1B, 2B ) with respect to the results when the antagonist was administered alone. However, in the future, more studies should be performed to demonstrate definitively that the antitumoral action of L-733,060 on both retinoblastoma cell lines is through the NK1 receptor.
Summarizing our results, the antitumoral activity of the NK1 receptor antagonist L-733,060 on retinoblastoma human cell 
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lines is described for the first time.
In addition, we demonstrate that SP is a mitogen of both cancer cell lines studied. These in vitro observations suggest that the inhibition of the SP/NK1 receptor system may be a useful novel treatment for the management of retinoblastoma disease.
